ACTINIUM PHARMACEUTICALS, INC. Net Income (Loss) Available to Common Stockholders, Basic
ACTINIUM PHARMACEUTICALS, INC. (ATNM) reported Net Income (Loss) Available to Common Stockholders, Basic of -$24.77 million for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-25.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2022-03-25
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-12-31 was -$8.01M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-09-30 was -$6.42M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-06-30 was -$5.02M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2021-03-31 was -$5.32M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2021 was -$24.77M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2020 was -$22.22M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2019 was -$21.90M.
- ACTINIUM PHARMACEUTICALS, INC. net income (loss) available to common stockholders, basic for fiscal 2018 was -$23.65M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 12 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$8.01M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$14.43M derived: sum of 2 quarters · filed 2022-03-25 | -$19.45M derived: sum of 3 quarters · filed 2022-03-25 | -$24.77M 10-K · filed 2022-03-25 | ||||
| 2021-09-30 | -$6.42M 10-Q · filed 2021-11-12 | -$11.44M derived: sum of 2 quarters · filed 2021-11-12 | -$16.76M 10-Q · filed 2021-11-12 | -$23.14M derived: sum of 4 quarters · filed 2022-03-25 | ||||
| 2021-06-30 | -$5.02M 10-Q · filed 2021-07-30 | -$10.34M 10-Q · filed 2021-07-30 | -$16.72M derived: sum of 3 quarters · filed 2022-03-25 | -$22.26M derived: sum of 4 quarters · filed 2022-03-25 | ||||
| 2021-03-31 | -$5.32M derived: 10-K 12 month − 3 quarters · filed 2022-03-25 | -$11.70M derived: sum of 2 quarters · filed 2022-03-25 | -$17.24M derived: sum of 3 quarters · filed 2022-03-25 | -$21.87M derived: sum of 4 quarters · filed 2022-03-25 | ||||
| 2020-12-31 | -$6.38M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$11.92M derived: sum of 2 quarters · filed 2022-03-25 | -$16.55M derived: sum of 3 quarters · filed 2022-03-25 | -$22.22M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | -$5.54M 10-Q · filed 2021-11-12 | -$10.17M derived: sum of 2 quarters · filed 2021-11-12 | -$15.84M 10-Q · filed 2021-11-12 | |||||
| 2020-06-30 | -$4.63M 10-Q · filed 2021-07-30 | -$10.30M 10-Q · filed 2021-07-30 | ||||||
| 2019-12-31 | -$4.60M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-31 | -$11.20M derived: sum of 2 quarters · filed 2021-03-31 | -$16.23M derived: sum of 3 quarters · filed 2021-03-31 | -$21.90M 10-K · filed 2021-03-31 | -$21.90M 10-K · filed 2020-05-08 | |||
| 2019-09-30 | -$6.60M 10-Q · filed 2020-10-23 | -$6.60M 10-Q · filed 2019-11-12 | -$11.63M derived: sum of 2 quarters · filed 2020-10-23 | -$17.30M 10-Q · filed 2020-10-23 | -$17.30M 10-Q · filed 2019-11-12 | |||
| 2019-06-30 | -$5.03M 10-Q · filed 2020-08-14 | -$5.03M 10-Q · filed 2019-08-09 | -$10.70M 10-Q · filed 2020-08-14 | -$10.70M 10-Q · filed 2019-08-09 | ||||
| 2018-12-31 | -$6.32M derived: 10-K 12 month − 10-Q 9 month · filed 2020-05-08 | -$12.47M derived: sum of 2 quarters · filed 2020-05-08 | -$17.33M derived: sum of 3 quarters · filed 2020-05-08 | -$23.65M 10-K · filed 2020-05-08 | ||||
| 2018-09-30 | -$6.15M 10-Q · filed 2019-11-12 | -$11.01M derived: sum of 2 quarters · filed 2019-11-12 | -$17.33M 10-Q · filed 2019-11-12 | |||||
| 2018-06-30 | -$4.86M 10-Q · filed 2019-08-09 | -$11.19M 10-Q · filed 2019-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |